Evidence map›Paper›PMID 25122553›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2014

Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements.

Aránzazu Mediero, Miguel Perez-Aso, Bruce N Cronstein

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Energy Regulation in Inflammatory Sarcopenia by the Purinergic System.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Modulation of the bacterial CobB sirtuin deacylase activity by N-terminal acetylation.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Article
  10. Adenosine AFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Adenosine ABritish journal of pharmacology · 2016
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aránzazu MedieroDepartment of Medicine, Division of Translational Medicine, New York University School of Medicine, New York, New York, USA.
Miguel Perez-AsoDepartment of Medicine, Division of Translational Medicine, New York University School of Medicine, New York, New York, USA.
Bruce N CronsteinDepartment of Medicine, Division of Translational Medicine, New York University School of Medicine, New York, New York, USA bruce.cronstein@nyumc.org.
New York University · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2012 to 2014
$16.8M
TRABECULAR BONE ADAPTATION TO MECHANICAL LOADINGP30AR046121 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI MYERS, ELIZABETH R. · 1999 to 2010
$5.5M
The Pharmacology of Dermal Fibrosis R01AR056672 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2009 to 2018
$4.6M
Purinergic Regulation of Bone MetabolismR01AR054897 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2008 to 2014
$2.1M
The Pharmacology of Dermal FibrosisR56AR056672 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2014 to 2014
$373k
NCATS NIH HHS UL1 TR000038NCATS NIH HHS UL1TR000038NCI NIH HHS P30CA16087-310NIAMS NIH HHS AR046121NIAMS NIH HHS AR54897NIAMS NIH HHS AR56672NIAMS NIH HHS AR56672S1NIAMS NIH HHS P30 AR046121NIAMS NIH HHS R01 AR054897NIAMS NIH HHS R01 AR056672NIAMS NIH HHS R56 AR056672
6 · The paper itself

Abstract

Bisphosphonates inhibit osteoclast differentiation/function via inhibition of Rap1A isoprenylation. As Rap1 is the effector of exchange protein directly activated by cAMP (EPAC) proteins, we determined the role of EPAC in osteoclast differentiation. We examined osteoclast differentiation as the number of primary murine/human bone-marrow precursors that differentiated into multinucleated TRAP-positive cells in the presence of EPAC-selective stimulus (8-pCTP-2'-O-Me-cAMP, 100 μM; 8-pCTP-2'-O-Me-cAMP-AM, 1 μM) or inhibitor brefeldin A (BFA), ESI-05, and ESI-09 (10 μM each). Rap1 activity was assessed, and signaling events, as well as differentiation in EPAC1/2-knockdown RAW264.7 cells, were studied. Direct EPAC1/2 stimulation significantly increased osteoclast differentiation, whereas EPAC1/2 inhibition diminished differentiation (113 ± 6%, P < 0.05, and 42 ± 10%, P < 0.001, of basal, respectively). Rap1 activation was maximal 15 min after RANKL stimulation (147 ± 9% of basal, P < 0.001), whereas silencing of EPAC1/2 diminished activated Rap1 (43 ± 13 and 20 ± 15% of control, P < 0.001) and NFkB nuclear translocation. TRAP-staining revealed no osteoclast differentiation in EPAC1/2-KO cells. Cathepsin K, NFATc1, and osteopontin mRNA expression decreased in EPAC1/2-KO cells when compared to control. RhoA, cdc42, Rac1, and FAK were activated in an EPAC1/2-dependent manner, and there was diminished cytoskeletal assembly in EPAC1/2-KO cells. In summary, EPAC1 and EPAC2 are critical signaling intermediates in osteoclast differentiation that permit RANKL-stimulated NFkB nuclear translocation and actin rearrangements. Targeting this signaling intermediate may diminish bone destruction in inflammatory arthritis.

Indexed as

Actin CytoskeletonActive Transport, Cell NucleusAnimalsCells, CulturedCyclic AMPCyclic AMP-Dependent Protein KinasesGuanine Nucleotide Exchange FactorsHumansHydrazonesIsoxazolesMiceNF-kappa BOsteoclastsRANK LigandSignal Transduction3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrileCyclic AMPCyclic AMP-Dependent Protein KinasesEpac protein, mouseGuanine Nucleotide Exchange FactorsHydrazonesIsoxazolesNF-kappa BRANK LigandRapgef4 protein, mousecdc42FAKRac1RhoA

Identifiers

PMID25122553
PMCPMC4200330
OpenAlexW2124444027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.